ResMed Inc (ASX:RMD)
A$ 28.61 +0.040 (+0.14%) Market Cap: 42.90 Bil Enterprise Value: 41.72 Bil PE Ratio: 19.17 PB Ratio: 4.44 GF Score: 98/100

Resmed Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 14, 2023 / 03:45PM GMT
Release Date Price: A$22.88 (-1.59%)
Travis Lee Steed
BofA Securities, Research Division - MD

I'm Travis Steed, the U.S. medical device analyst at Bank of America. And the last session of the day, where -- save the best for last, we've got ResMed here. Rob Douglas, President and Chief Operating Officer; and Amy Wakeham, head of Investor Relations. Thanks for joining. I think Rob I was going to hand it over to you to make a few opening remarks and if you will, and we can jump into some Q&A.

Robert A. Douglas
ResMed Inc. - President & COO

Sure. Thanks, Travis. Just briefly, if you don't know ResMed, we're best known for treating sleep apnea, but we actually do a lot more than that and we've got really good software businesses, and we're very focused on our COPD treatments as well. As I said, the bulk of our business is treating obstructive sleep apnea, and we're way ahead the market leader in that. And it's a very good market for us. we think the total addressable market is probably close to 1 billion people. It's a very common condition, and we've seen prevalence increasing over the years

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot